Huarun Jiangzhong Pharmaceutical Group Co., Ltd.
Jiangzhong Pharmaceutical Co., Ltd. (referred to as "Jiangzhong Pharmaceutical" or "Company") achieved backdoor listing through reorganization of Jiangxi Dongfeng Pharmaceutical Co., Ltd. in 1999. The stock abbreviation is Jiangzhong Pharmaceutical, with the stock code 600750. The company takes the traditional Chinese medicine industry as the core, combines traditional Chinese medicine theory with modern scientific research and technology platforms, and is mainly engaged in the research, development, production and sales of Chinese patent medicines and health foods, including "Jiangzhong", "Chuyuan" and "Yang Jisheng". , "Sanghai" and other trademarks, brand products include Jiangzhong Brand Jianweixiaoshi Tablets, Jiangzhong Brand Compound Grass Coral Lozenges, Lihuo Brand Lactobacillin Tablets, Chuyuan Brand Compound Amino Acid Oral Liquid, Shenling Grass Oral Liquid, Bo Locke, compound fresh bamboo juice liquid, Paishi Granules Sanghai Jinwei, Bazhen Yimu Capsules, etc. After years of development, the company has formed its own core expertise and capabilities in scientific research, production, marketing, etc. In terms of R&D, the R&D strength will be improved by relying on the "National Engineering Research Center for Solid Preparation Manufacturing Technology of Traditional Chinese Medicine", "Jiangzhong Pharmaceutical Base, Key Laboratory of Aerospace Nutrition and Food Engineering" and other engineering research centers and key laboratories; in terms of production, the company was the state in 2019 The Ministry of Ecology and Environment has rated it as the "China Ecological Civilization Award Advanced Collective".
Huarun Jiangzhong Pharmaceutical Group Co., Ltd.
Jiangzhong Pharmaceutical Co., Ltd. (referred to as "Jiangzhong Pharmaceutical" or "Company") achieved backdoor listing through reorganization of Jiangxi Dongfeng Pharmaceutical Co., Ltd. in 1999. The stock abbreviation is Jiangzhong Pharmaceutical, with the stock code 600750. The company takes the traditional Chinese medicine industry as the core, combines traditional Chinese medicine theory with modern scientific research and technology platforms, and is mainly engaged in the research, development, production and sales of Chinese patent medicines and health foods, including "Jiangzhong", "Chuyuan" and "Yang Jisheng". , "Sanghai" and other trademarks, brand products include Jiangzhong Brand Jianweixiaoshi Tablets, Jiangzhong Brand Compound Grass Coral Lozenges, Lihuo Brand Lactobacillin Tablets, Chuyuan Brand Compound Amino Acid Oral Liquid, Shenling Grass Oral Liquid, Bo Locke, compound fresh bamboo juice liquid, Paishi Granules Sanghai Jinwei, Bazhen Yimu Capsules, etc. After years of development, the company has formed its own core expertise and capabilities in scientific research, production, marketing, etc. In terms of R&D, the R&D strength will be improved by relying on the "National Engineering Research Center for Solid Preparation Manufacturing Technology of Traditional Chinese Medicine", "Jiangzhong Pharmaceutical Base, Key Laboratory of Aerospace Nutrition and Food Engineering" and other engineering research centers and key laboratories; in terms of production, the company was the state in 2019 The Ministry of Ecology and Environment has rated it as the "China Ecological Civilization Award Advanced Collective".
Bozhou Leanqe Medical Technology Co., Ltd.
Bozhou Leanqe Medical Technology Co., Ltd. is located in the High-tech Zone of Bozhou city. It is a high-tech enterprise integrating R&D, production and sales of medical devices, covering an area of 50 acres. We have established R&D center and operation center in Shenzhen city and Hefei city, and have R&D offices in the United States. We`re committed to the R&D, innovation and industrialization of medical products, and have a number of independent intellectual property rights. Our products cover three major fields: minimally invasive medical, life monitoring and rehabilitation medical, and provide overall solutions.
Bozhou Leanqe Medical Technology Co., Ltd.
Bozhou Leanqe Medical Technology Co., Ltd. is located in the High-tech Zone of Bozhou city. It is a high-tech enterprise integrating R&D, production and sales of medical devices, covering an area of 50 acres. We have established R&D center and operation center in Shenzhen city and Hefei city, and have R&D offices in the United States. We`re committed to the R&D, innovation and industrialization of medical products, and have a number of independent intellectual property rights. Our products cover three major fields: minimally invasive medical, life monitoring and rehabilitation medical, and provide overall solutions.
Ningbo Yaoming Medical Technology Co., Ltd.
Ningbo Yaoming Medical Technology Co., Ltd. is located in Ningbo City, Zhejiang Province, on the coast of the East China Sea.Yaoming Medical Technology Company has always prioritized research and innovation as its foundation, sales channels as its basis, digital solutions as its guide, and clinic terminal demands as its orientation. The company adheres to the principles of scientific development and people-oriented approach, boasting a comprehensive management team, robust technical team, stable sales team, and distribution channels.lt has established deep collaborations with relevant hospitals, frontline doctorsand universities, among others, to enhance the "industry-university-research-application" independent innovation model and foster synergistic innovation to empower industry development.Yaoming Medical has always been at the forefront of exploration in the field of minimally invasive surgical instruments and accessories(MISIA),particularly in the MISIA market.With a focus on products such as carbon dioxide insufflators and disposable sterile trocar systems for laparoscopic insufflation,we has achieved significant breakthroughs in technology after long-term research and development efforts.It has successfully overcome technological barriers from foreign sources and pioneered the development of a brand-new laparoscopic insufflation system. After multiple rounds of testing, the performance of the system is on par with high-end foreign products.We has always been dedicated to technological innovation, aiming to provide excellent and comprehensive solutions in the field of minimally invasive surgical instruments for doctors and patients alike.lts commitment extends to expanding the path of the global minimally invasive surgical medical deviceindustry in China.
Ningbo Yaoming Medical Technology Co., Ltd.
Ningbo Yaoming Medical Technology Co., Ltd. is located in Ningbo City, Zhejiang Province, on the coast of the East China Sea.Yaoming Medical Technology Company has always prioritized research and innovation as its foundation, sales channels as its basis, digital solutions as its guide, and clinic terminal demands as its orientation. The company adheres to the principles of scientific development and people-oriented approach, boasting a comprehensive management team, robust technical team, stable sales team, and distribution channels.lt has established deep collaborations with relevant hospitals, frontline doctorsand universities, among others, to enhance the "industry-university-research-application" independent innovation model and foster synergistic innovation to empower industry development.Yaoming Medical has always been at the forefront of exploration in the field of minimally invasive surgical instruments and accessories(MISIA),particularly in the MISIA market.With a focus on products such as carbon dioxide insufflators and disposable sterile trocar systems for laparoscopic insufflation,we has achieved significant breakthroughs in technology after long-term research and development efforts.It has successfully overcome technological barriers from foreign sources and pioneered the development of a brand-new laparoscopic insufflation system. After multiple rounds of testing, the performance of the system is on par with high-end foreign products.We has always been dedicated to technological innovation, aiming to provide excellent and comprehensive solutions in the field of minimally invasive surgical instruments for doctors and patients alike.lts commitment extends to expanding the path of the global minimally invasive surgical medical deviceindustry in China.
Guilin Sanjin Pharmaceutical Co., Ltd.
Guilin Sanjin Pharmaceutical Co., Ltd. is the core enterprise of Sanjin Group. It mainly engages in the research and development and production of traditional Chinese medicine and natural medicines. It is one of the earliest manufacturers in China to produce modern Chinese medicine preparations. Since 1985, Guilin Sanjin has insisted on reform and innovation, relying on scientific and technological progress and scientific management, and has transformed from an unknown small traditional Chinese medicine workshop into a nationally renowned modern traditional Chinese medicine enterprise. As a well-known high-tech enterprise inside and outside the district, Sanjin has established innovative platforms such as nationally recognized enterprise technology centers, postdoctoral research workstations and Guangxi Institute of Traditional Chinese Medicine Industrialization Engineering. Over the years, we have been committed to promoting and implementing the modernization plan of the traditional Chinese medicine industry and actively cultivating and improving the independent innovation capabilities of enterprises. The company's new special Chinese medicines are all developed by the enterprise technology center. At present, Sanjin has more than 200 registered varieties and 13 pharmaceutical dosage forms, and has 42 special varieties independently developed by Guilin Watermelon Cream, Watermelon Cream Throat Soft Tablets, Sanjin Tablets, Naomaitai Capsules, etc. After years of hard work, Sanjin has formed strong professional and market advantages in throat, oral medication and urinary system medication. Its representative products, Sanjin Watermelon Cream Series and Sanjin Tablets, have been at the forefront of similar Chinese patent medicines in the country for many years. In July 2009, Guilin Sanjin successfully entered the capital market with a new look of high growth and high efficiency, and ushered in a new stage of rapid development of the enterprise. In recent years, in order to actively respond to the call of Guilin Municipal Party Committee and Municipal Government to "develop westward and create a new Guilin", and to resolve the contradiction between the dispersed production bases and warehousing facilities of enterprises and the rapid development of enterprises, Sanjin has launched the "Sanjin". The construction of the modern traditional Chinese medicine industrialization technology transformation project. At present, the first phase of the project has been officially put into production and the overall relocation of the main production lines has been achieved. Facing the future, Sanjin will uphold the corporate mission of "innovation to promote pharmaceutical progress" and the corporate spirit of "dare to be the first", implement the "one body and two wings" development strategy with traditional Chinese medicine as the main body and committed to developing biopharmaceuticals and the big health industry, Quality and reputation are the first life of the enterprise, breakthroughs and innovation, continuously enhances the competitive strength of Sanjin, and is enterprising, with the goal of developing to serve the country and repay investors, and with the goal of building China's advanced pharmaceutical manufacturing group, we will promote the modernization and internationalization of the traditional Chinese medicine industry!
Guilin Sanjin Pharmaceutical Co., Ltd.
Guilin Sanjin Pharmaceutical Co., Ltd. is the core enterprise of Sanjin Group. It mainly engages in the research and development and production of traditional Chinese medicine and natural medicines. It is one of the earliest manufacturers in China to produce modern Chinese medicine preparations. Since 1985, Guilin Sanjin has insisted on reform and innovation, relying on scientific and technological progress and scientific management, and has transformed from an unknown small traditional Chinese medicine workshop into a nationally renowned modern traditional Chinese medicine enterprise. As a well-known high-tech enterprise inside and outside the district, Sanjin has established innovative platforms such as nationally recognized enterprise technology centers, postdoctoral research workstations and Guangxi Institute of Traditional Chinese Medicine Industrialization Engineering. Over the years, we have been committed to promoting and implementing the modernization plan of the traditional Chinese medicine industry and actively cultivating and improving the independent innovation capabilities of enterprises. The company's new special Chinese medicines are all developed by the enterprise technology center. At present, Sanjin has more than 200 registered varieties and 13 pharmaceutical dosage forms, and has 42 special varieties independently developed by Guilin Watermelon Cream, Watermelon Cream Throat Soft Tablets, Sanjin Tablets, Naomaitai Capsules, etc. After years of hard work, Sanjin has formed strong professional and market advantages in throat, oral medication and urinary system medication. Its representative products, Sanjin Watermelon Cream Series and Sanjin Tablets, have been at the forefront of similar Chinese patent medicines in the country for many years. In July 2009, Guilin Sanjin successfully entered the capital market with a new look of high growth and high efficiency, and ushered in a new stage of rapid development of the enterprise. In recent years, in order to actively respond to the call of Guilin Municipal Party Committee and Municipal Government to "develop westward and create a new Guilin", and to resolve the contradiction between the dispersed production bases and warehousing facilities of enterprises and the rapid development of enterprises, Sanjin has launched the "Sanjin". The construction of the modern traditional Chinese medicine industrialization technology transformation project. At present, the first phase of the project has been officially put into production and the overall relocation of the main production lines has been achieved. Facing the future, Sanjin will uphold the corporate mission of "innovation to promote pharmaceutical progress" and the corporate spirit of "dare to be the first", implement the "one body and two wings" development strategy with traditional Chinese medicine as the main body and committed to developing biopharmaceuticals and the big health industry, Quality and reputation are the first life of the enterprise, breakthroughs and innovation, continuously enhances the competitive strength of Sanjin, and is enterprising, with the goal of developing to serve the country and repay investors, and with the goal of building China's advanced pharmaceutical manufacturing group, we will promote the modernization and internationalization of the traditional Chinese medicine industry!
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Wanglaoji herbal tea was born in 1828 during the Daoguang period of the Qing Dynasty. It is recognized as the founder of herbal tea. It has a long history of nearly two hundred years and is a representative of Chinese traditional herbal tea culture. Guangzhou Wanglaoji Health Industry Co., Ltd. is a member unit of Guangzhou Pharmaceutical Group. Since its establishment, the company has been deeply involved in the fast-moving consumer beverage industry and has launched Wanglaoji Red Cans and Red Bottle Series Herbal Tea Products, as well as Thorny Lyrics Natural High-dimensional C Beverage, Li Xiaoji Litchi Drinks, coconut coconut milk, Dazhai walnut decoction and other products. Currently, it has 10 wholly-owned subsidiaries, 1 joint venture and 1 branch, with more than 10,000 employees. It is an industry leader in the Chinese herbal tea industry with high market share, large sales scale and wide brand influence. Brands with considerable influence and popularity at home and abroad. Wanglaoji Health Company mainly focuses on herbal tea. After years of market cultivation, it has developed more than 10 million terminal outlets nationwide. Its products are sold well at home and abroad, with annual sales exceeding 10 billion yuan, and successfully occupying 70% of the market share of the herbal tea industry. Wanglaoji Health Company inherits and promotes the Wanglaoji brand worth hundreds of billions. Guided by the "fashion, technology, and culture" font-shaped development strategy, it has created Wanglaoji's "auspicious culture" and "afraid of getting angry culture", making "afraid of getting angry culture" The spreading slogans of "Drink Wanglaoji" and "Celebrate auspicious New Year, drink Wanglaoji" are deeply rooted in people's hearts. The brand rejuvenation construction that Wanglaoji Health Company continues to promote continuously stimulates the brand's youthful vitality. Wanglaoji Health Company's overall channel layout strategy achieves full coverage of traditional channels, catering channels, gift channels, ready-to-drink channels, special channels, and e-commerce channels, so as to achieve "Wanglaoji wherever there is water selling." Among them, the sales volume of catering channels has reached the forefront of all canned beverages. The gift market that has been creatively cultivated and upgraded has also made Wanglaoji herbal tea a product with a high share of gift-giving in the Chinese beverage market. At the same time, it is deployed in overseas markets, and its products are exported to nearly 60 countries and regions around the world, basically covering the overseas Chinese market. Looking to the future, Wanglaoji Health Company will uphold the Wanglaoji spirit of "loyalty to the enterprise, courage to take responsibility, willing to contribute, good at learning, practice hard and achieve mission", and implement the four-in-one integration of fashion, digital, innovation, and responsibility. "Strategic measures to strive to realize the corporate vision of Wanglaoji Health Company to strive to create "Global Beverage NO.1" and complete the corporate mission of "making the world more auspicious".
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Wanglaoji herbal tea was born in 1828 during the Daoguang period of the Qing Dynasty. It is recognized as the founder of herbal tea. It has a long history of nearly two hundred years and is a representative of Chinese traditional herbal tea culture. Guangzhou Wanglaoji Health Industry Co., Ltd. is a member unit of Guangzhou Pharmaceutical Group. Since its establishment, the company has been deeply involved in the fast-moving consumer beverage industry and has launched Wanglaoji Red Cans and Red Bottle Series Herbal Tea Products, as well as Thorny Lyrics Natural High-dimensional C Beverage, Li Xiaoji Litchi Drinks, coconut coconut milk, Dazhai walnut decoction and other products. Currently, it has 10 wholly-owned subsidiaries, 1 joint venture and 1 branch, with more than 10,000 employees. It is an industry leader in the Chinese herbal tea industry with high market share, large sales scale and wide brand influence. Brands with considerable influence and popularity at home and abroad. Wanglaoji Health Company mainly focuses on herbal tea. After years of market cultivation, it has developed more than 10 million terminal outlets nationwide. Its products are sold well at home and abroad, with annual sales exceeding 10 billion yuan, and successfully occupying 70% of the market share of the herbal tea industry. Wanglaoji Health Company inherits and promotes the Wanglaoji brand worth hundreds of billions. Guided by the "fashion, technology, and culture" font-shaped development strategy, it has created Wanglaoji's "auspicious culture" and "afraid of getting angry culture", making "afraid of getting angry culture" The spreading slogans of "Drink Wanglaoji" and "Celebrate auspicious New Year, drink Wanglaoji" are deeply rooted in people's hearts. The brand rejuvenation construction that Wanglaoji Health Company continues to promote continuously stimulates the brand's youthful vitality. Wanglaoji Health Company's overall channel layout strategy achieves full coverage of traditional channels, catering channels, gift channels, ready-to-drink channels, special channels, and e-commerce channels, so as to achieve "Wanglaoji wherever there is water selling." Among them, the sales volume of catering channels has reached the forefront of all canned beverages. The gift market that has been creatively cultivated and upgraded has also made Wanglaoji herbal tea a product with a high share of gift-giving in the Chinese beverage market. At the same time, it is deployed in overseas markets, and its products are exported to nearly 60 countries and regions around the world, basically covering the overseas Chinese market. Looking to the future, Wanglaoji Health Company will uphold the Wanglaoji spirit of "loyalty to the enterprise, courage to take responsibility, willing to contribute, good at learning, practice hard and achieve mission", and implement the four-in-one integration of fashion, digital, innovation, and responsibility. "Strategic measures to strive to realize the corporate vision of Wanglaoji Health Company to strive to create "Global Beverage NO.1" and complete the corporate mission of "making the world more auspicious".
Jiangsu Changmei Medtech Co., Ltd.
Jiangsu Changmei Medtech Co., Ltd. was founded in 2013 and specializes in the design, research, and production of all kinds of minimally invasive medical devices, with a particular focus on the kyphoplasty system products, dilation balloon catheter products, and endoscopic products, which are all CE certificated, we have a comprehensive strength from the original design, development to batch production.
Our team members have experience and background in different industries in enterprise processes and applications. We cultivate our team with professionalism and pursuit of perfection. Through nearly 10 years of effort, the kyphoplasty balloon catheter already accounts for 80% of the Chinese market, and we also have good cooperation relationships with customers all over the world, including the member companies of Stryker and Medtronic.
We are committed to the development of state-of-the-art and challengeable endoscope products, our 1.0mm mini biopsy forceps, the novel definition of "MADE IN CHINA", the first in China, are compatible with a 1.20mm instrument channel to allow successful sampling. The four-bar linkage structure and alligator tooth cup, which are with stronger push ability and enable a reliable biopsy even in the small bronchi.
The great feedback from the market earns more confidence and determination for the following new product research and development. We will continue to be committed to innovative minimally invasive medical solutions, providing better medical balloon catheters and endoscopy products for patients around the world, improving people's lives, and improving the health quality of patients around the world.
Jiangsu Changmei Medtech Co., Ltd.
Jiangsu Changmei Medtech Co., Ltd. was founded in 2013 and specializes in the design, research, and production of all kinds of minimally invasive medical devices, with a particular focus on the kyphoplasty system products, dilation balloon catheter products, and endoscopic products, which are all CE certificated, we have a comprehensive strength from the original design, development to batch production.
Our team members have experience and background in different industries in enterprise processes and applications. We cultivate our team with professionalism and pursuit of perfection. Through nearly 10 years of effort, the kyphoplasty balloon catheter already accounts for 80% of the Chinese market, and we also have good cooperation relationships with customers all over the world, including the member companies of Stryker and Medtronic.
We are committed to the development of state-of-the-art and challengeable endoscope products, our 1.0mm mini biopsy forceps, the novel definition of "MADE IN CHINA", the first in China, are compatible with a 1.20mm instrument channel to allow successful sampling. The four-bar linkage structure and alligator tooth cup, which are with stronger push ability and enable a reliable biopsy even in the small bronchi.
The great feedback from the market earns more confidence and determination for the following new product research and development. We will continue to be committed to innovative minimally invasive medical solutions, providing better medical balloon catheters and endoscopy products for patients around the world, improving people's lives, and improving the health quality of patients around the world.
Guilong Pharmaceutical (Anhui) Co., Ltd.
In 1989, Guilong Pharmaceutical carried the huge waves of the traditional Eastern culture of thousands of years. "Guilong" symbolizes the green osmanthus trees in all seasons. The fragrance spreads thousands of miles and is simple and elegant. It is the embodiment of traditional Chinese medicine; "Dragon" symbolizes the East. Culture and the power to build momentum. Since its establishment, the company has been aiming to "inherit the essence of Chinese medicine and be healthy for the people" and continue to research and innovate scientific research. The Slow Yan Shuning brand under Guilong Pharmaceutical is one of the innovative brands that inherits the classic prescriptions of court medical cases in the Qing Dynasty and creates "China's leading brand of throat health". Good products are the foundation of a company's life, and conscientious medicine is the source of trust in the people. A good reputation and corporate brand image are achieved through their own product strength. Slow Yan Shuning, focusing on the field of throat health, has established a good corporate image in the industry and consumers' minds with the significant efficacy and safety performance of the products. It has been on the Healthy China Brand List for many years and has become a model of drug safety. The reason why Yan Shuning achieved such brilliant achievements is inseparable from her own continuous research and development and innovation and continuous excellence. Based on R&D, the company aims to be a professional throat health brand in China and a brand responsible for consumers' health. Brand strategy is an important part of Guilong's soft power. Guilong’s management believes that “the success of a company is ultimately reflected in the success of the brand.” This is what the Guilong people think and do the same. Slow Yan Shuning’s professional brand and quality have brought good news to the people’s throat health, but it has not slacked off and stopped here. Instead, it has always adhered to concept innovation, management innovation, technological innovation, and job innovation, and conducted in-depth research on the needs of patients with throat disease. , constantly launch new products to meet the different needs of throat problems from light to severe, and comprehensively solve throat problems. It has products such as Qingluo Liyu Granules, Haoshuang Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft The granules were rated as "a key category of over-the-counter drugs in China" by the China Over-the-counter Drug Association.
Guilong Pharmaceutical (Anhui) Co., Ltd.
In 1989, Guilong Pharmaceutical carried the huge waves of the traditional Eastern culture of thousands of years. "Guilong" symbolizes the green osmanthus trees in all seasons. The fragrance spreads thousands of miles and is simple and elegant. It is the embodiment of traditional Chinese medicine; "Dragon" symbolizes the East. Culture and the power to build momentum. Since its establishment, the company has been aiming to "inherit the essence of Chinese medicine and be healthy for the people" and continue to research and innovate scientific research. The Slow Yan Shuning brand under Guilong Pharmaceutical is one of the innovative brands that inherits the classic prescriptions of court medical cases in the Qing Dynasty and creates "China's leading brand of throat health". Good products are the foundation of a company's life, and conscientious medicine is the source of trust in the people. A good reputation and corporate brand image are achieved through their own product strength. Slow Yan Shuning, focusing on the field of throat health, has established a good corporate image in the industry and consumers' minds with the significant efficacy and safety performance of the products. It has been on the Healthy China Brand List for many years and has become a model of drug safety. The reason why Yan Shuning achieved such brilliant achievements is inseparable from her own continuous research and development and innovation and continuous excellence. Based on R&D, the company aims to be a professional throat health brand in China and a brand responsible for consumers' health. Brand strategy is an important part of Guilong's soft power. Guilong’s management believes that “the success of a company is ultimately reflected in the success of the brand.” This is what the Guilong people think and do the same. Slow Yan Shuning’s professional brand and quality have brought good news to the people’s throat health, but it has not slacked off and stopped here. Instead, it has always adhered to concept innovation, management innovation, technological innovation, and job innovation, and conducted in-depth research on the needs of patients with throat disease. , constantly launch new products to meet the different needs of throat problems from light to severe, and comprehensively solve throat problems. It has products such as Qingluo Liyu Granules, Haoshuang Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft Soft The granules were rated as "a key category of over-the-counter drugs in China" by the China Over-the-counter Drug Association.
Zhejiang Conba Pharmaceutical Co., Ltd.
Zhejiang Kangenbei Pharmaceutical Co., Ltd. was formerly Lanxi Yunshan Pharmaceutical Factory. After more than 50 years of development, it has grown into a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales. (SH600572) ). The company's controlling shareholder is Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. (a wholly-owned subsidiary of Zhejiang International Trade Group Co., Ltd.). The company is headquartered in Hangzhou, with Zhejiang as the industrial development center, and has established industrial bases in Jiangxi, Yunnan, Inner Mongolia and other provinces, with a total employee population of more than 8,000. The company has innovative platforms such as national innovative enterprises, national enterprise technology centers and postdoctoral research workstations, academician workstations, provincial key laboratory of traditional Chinese medicine and pharmaceutical technology, and provincial key enterprise research institutes. It has the following innovative platforms such as Kangenbe, Qianlikang, Tianbaoning and A big brand matrix represented by well-known brands such as Jindi and Jinaokang. Since it was officially included in the management system of the Provincial China Trade Group in July 2020, the company has taken "inheritance and integrity and innovation" as its fundamental guideline, focusing on core business, innovative development, and value improvement, laying a good foundation for building the main platform for traditional Chinese medicine and health industry in Zhejiang Province. . In the future, the company will focus on the development goals of the life and health industry of the Provincial Guomao Group, give full play to the advantages of the mixed reform system and mechanism, increase efforts to deepen the field of traditional Chinese medicine and health, and strive to make new breakthroughs in innovative platform construction, resource integration and development, and management quality improvement and efficiency improvement. , iterates its own competitiveness in the new development ecosystem, and becomes an important force in our province to build a highland for life, health, science and technology innovation, and contributes Kangenbei's strength to help the strong province of traditional Chinese medicine and high-quality development to build a demonstration zone for common prosperity.
Zhejiang Conba Pharmaceutical Co., Ltd.
Zhejiang Kangenbei Pharmaceutical Co., Ltd. was formerly Lanxi Yunshan Pharmaceutical Factory. After more than 50 years of development, it has grown into a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales. (SH600572) ). The company's controlling shareholder is Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. (a wholly-owned subsidiary of Zhejiang International Trade Group Co., Ltd.). The company is headquartered in Hangzhou, with Zhejiang as the industrial development center, and has established industrial bases in Jiangxi, Yunnan, Inner Mongolia and other provinces, with a total employee population of more than 8,000. The company has innovative platforms such as national innovative enterprises, national enterprise technology centers and postdoctoral research workstations, academician workstations, provincial key laboratory of traditional Chinese medicine and pharmaceutical technology, and provincial key enterprise research institutes. It has the following innovative platforms such as Kangenbe, Qianlikang, Tianbaoning and A big brand matrix represented by well-known brands such as Jindi and Jinaokang. Since it was officially included in the management system of the Provincial China Trade Group in July 2020, the company has taken "inheritance and integrity and innovation" as its fundamental guideline, focusing on core business, innovative development, and value improvement, laying a good foundation for building the main platform for traditional Chinese medicine and health industry in Zhejiang Province. . In the future, the company will focus on the development goals of the life and health industry of the Provincial Guomao Group, give full play to the advantages of the mixed reform system and mechanism, increase efforts to deepen the field of traditional Chinese medicine and health, and strive to make new breakthroughs in innovative platform construction, resource integration and development, and management quality improvement and efficiency improvement. , iterates its own competitiveness in the new development ecosystem, and becomes an important force in our province to build a highland for life, health, science and technology innovation, and contributes Kangenbei's strength to help the strong province of traditional Chinese medicine and high-quality development to build a demonstration zone for common prosperity.
Shandong Hongjitang Pharmaceutical Group Co., Ltd.
The world's traditional Chinese medicine, the century-old Hongjitang. Shandong Hongjitang Pharmaceutical Group Co., Ltd. was founded in 1907 and has a history of more than 110 years. On the basis of inheriting the essence and adhering to the truth and innovation, it has established a modern Hongjitang Traditional Chinese Medicine Health City from a high starting point, completing the traditional manufacturing type to The leap of technology-leading has formed core competitiveness in many aspects. Hongjitang Pharmaceutical currently has 151 documents, and its products cover Chinese patent medicines, formula granules, Chinese herbal medicines, raw materials, donkey-hide gelatin and healthy foods. 35 products have entered the national basic medicine catalog and 90 products have entered the medical insurance catalog. There are 10 large dosage forms (pills, powders, tablets, mixtures, tinctures, gels, capsules, granules, decoctions, oral liquids), and 10 exclusive products (Qianlixin Capsules, Musk Heartburnin Tablets, Jinming Tablets , Compound Xiling Jiedu Capsules, Deer Bone Gum, Hailong Gecko Oral Liquid, Zhaqi Wan, Shuqi Wan, Jiawei Xiangsha Zhishu Wan, Musk Ketone). 10 products are listed as recommended medications for the diagnosis and treatment of new pneumonia (Huoxiang Zhengqi Water, Fangfeng Tongsheng Pills, Angong Niuhuang Pills, Suhexiang Pills, Comfang Xiling Jiedu Capsules/Pills, Lung Clearing and Detoxification Compound, Jinbei Oral Liquid, Qingwen Jiedu Pills, Qipi Pills). In terms of business model and network channels, Hongjitang OTC Pharmaceuticals directly supplies chain pharmacies, adopts the front-store and back-factory model to establish cooperation with more than 80% of the top 100 pharmaceutical chains in the country, and has cooperated with more than 100,000 pharmacies. Through cooperation with nationally renowned commercial companies such as China Resources, Jiuzhoutong, and Sinopharm Holdings, medical products have formed a sales network covering national-level hospitals and primary medical and health service centers, such as Qianlixin Capsules, Musk Heartburnin Tablets, Xuefu Zhuyu Oral Liquid, etc. The clinical efficacy of high-quality products is highly recognized by experts. Supermarket e-commerce channels directly sell the healthy food series to large domestic chain drug retailers, supermarkets, traditional Chinese medicine clinics and other terminals, and provide customers with products through online platforms such as JD.com and Tmall. Hongjitang Pharmaceutical has enhanced its core competitiveness through innovation, and has more than 10 scientific research and innovation platforms, including Shandong Traditional Chinese Medicine Technology Innovation Center for the Treatment of Respiratory Diseases, Traditional Chinese Medicine Development Strategy Research Center, Shandong Postdoctoral Innovation Practice Base, etc., and undertakes the country and province. Research on many major projects at the level. We cooperate closely with many academicians, national medical masters, and well-known scientific research institutes to hire many famous old Chinese medicine doctors to serve as honorary deans of the institute. On the one hand, we will carry out dosage form improvement, process improvement, clinical re-evaluation and other second rounds around the existing 151 document numbers. Development and research; on the other hand, focus on the advantages of traditional Chinese medicine, and carry out research in the directions of new traditional Chinese medicine, classic prescriptions, formula granules, and replacement of rare and precious medicinal materials. Jinbei Oral Liquid was approved as a preparation for medical institutions in Shandong Province in January 2020 and used for the treatment of new crown patients across the province. It is expected to become an innovative Chinese medicine for the treatment of pulmonary fibrosis. The artificial replacement project of Chansu is expected to fill the gap in new Chinese patent medicines. Hongjitang Pharmaceuticals is a designated enterprise for the production of lung clearing and detoxifying agents approved by the Shandong Provincial Health Commission, the Provincial Administration of Traditional Chinese Medicine and the Provincial Drug Administration. As the first batch of enterprises in Shandong Province's traditional Chinese medicine formula granules research, the first phase of the 3,000-ton formula granules project has been put into production. According to the path from the provincial standard to the national standard, it will lead the research on formula granules standards in Shandong Province. After all, 600 varieties will be realized. Production.
Shandong Hongjitang Pharmaceutical Group Co., Ltd.
The world's traditional Chinese medicine, the century-old Hongjitang. Shandong Hongjitang Pharmaceutical Group Co., Ltd. was founded in 1907 and has a history of more than 110 years. On the basis of inheriting the essence and adhering to the truth and innovation, it has established a modern Hongjitang Traditional Chinese Medicine Health City from a high starting point, completing the traditional manufacturing type to The leap of technology-leading has formed core competitiveness in many aspects. Hongjitang Pharmaceutical currently has 151 documents, and its products cover Chinese patent medicines, formula granules, Chinese herbal medicines, raw materials, donkey-hide gelatin and healthy foods. 35 products have entered the national basic medicine catalog and 90 products have entered the medical insurance catalog. There are 10 large dosage forms (pills, powders, tablets, mixtures, tinctures, gels, capsules, granules, decoctions, oral liquids), and 10 exclusive products (Qianlixin Capsules, Musk Heartburnin Tablets, Jinming Tablets , Compound Xiling Jiedu Capsules, Deer Bone Gum, Hailong Gecko Oral Liquid, Zhaqi Wan, Shuqi Wan, Jiawei Xiangsha Zhishu Wan, Musk Ketone). 10 products are listed as recommended medications for the diagnosis and treatment of new pneumonia (Huoxiang Zhengqi Water, Fangfeng Tongsheng Pills, Angong Niuhuang Pills, Suhexiang Pills, Comfang Xiling Jiedu Capsules/Pills, Lung Clearing and Detoxification Compound, Jinbei Oral Liquid, Qingwen Jiedu Pills, Qipi Pills). In terms of business model and network channels, Hongjitang OTC Pharmaceuticals directly supplies chain pharmacies, adopts the front-store and back-factory model to establish cooperation with more than 80% of the top 100 pharmaceutical chains in the country, and has cooperated with more than 100,000 pharmacies. Through cooperation with nationally renowned commercial companies such as China Resources, Jiuzhoutong, and Sinopharm Holdings, medical products have formed a sales network covering national-level hospitals and primary medical and health service centers, such as Qianlixin Capsules, Musk Heartburnin Tablets, Xuefu Zhuyu Oral Liquid, etc. The clinical efficacy of high-quality products is highly recognized by experts. Supermarket e-commerce channels directly sell the healthy food series to large domestic chain drug retailers, supermarkets, traditional Chinese medicine clinics and other terminals, and provide customers with products through online platforms such as JD.com and Tmall. Hongjitang Pharmaceutical has enhanced its core competitiveness through innovation, and has more than 10 scientific research and innovation platforms, including Shandong Traditional Chinese Medicine Technology Innovation Center for the Treatment of Respiratory Diseases, Traditional Chinese Medicine Development Strategy Research Center, Shandong Postdoctoral Innovation Practice Base, etc., and undertakes the country and province. Research on many major projects at the level. We cooperate closely with many academicians, national medical masters, and well-known scientific research institutes to hire many famous old Chinese medicine doctors to serve as honorary deans of the institute. On the one hand, we will carry out dosage form improvement, process improvement, clinical re-evaluation and other second rounds around the existing 151 document numbers. Development and research; on the other hand, focus on the advantages of traditional Chinese medicine, and carry out research in the directions of new traditional Chinese medicine, classic prescriptions, formula granules, and replacement of rare and precious medicinal materials. Jinbei Oral Liquid was approved as a preparation for medical institutions in Shandong Province in January 2020 and used for the treatment of new crown patients across the province. It is expected to become an innovative Chinese medicine for the treatment of pulmonary fibrosis. The artificial replacement project of Chansu is expected to fill the gap in new Chinese patent medicines. Hongjitang Pharmaceuticals is a designated enterprise for the production of lung clearing and detoxifying agents approved by the Shandong Provincial Health Commission, the Provincial Administration of Traditional Chinese Medicine and the Provincial Drug Administration. As the first batch of enterprises in Shandong Province's traditional Chinese medicine formula granules research, the first phase of the 3,000-ton formula granules project has been put into production. According to the path from the provincial standard to the national standard, it will lead the research on formula granules standards in Shandong Province. After all, 600 varieties will be realized. Production.
Yunnan Panlongyunhai Pharmaceutical Trading Co., Ltd.
Yunnan Panlong Yunhai Pharmaceutical Group Co., Ltd. (Yunnan Panlong Yunhai Pharmaceutical Management Co., Ltd. is an affiliated enterprise of Yunnan Panlong Yunhai Pharmaceutical Group Co., Ltd.) was founded in January 1994. It is a drug development, development and production. International pharmaceutical enterprise group integrating sales, the company actively innovates and explores management theories and development models suitable for the development and growth of Chinese private enterprises, and innovatively proposes traditional Chinese medicine health care that "detoxification and health care" and "internal adjustment and external care, healthy and beautiful" Theory has created a new era of detoxification and health preservation in China. The company's headquarters is located in Kunming High-tech Industrial Development Zone. Panlong Yunhai Production Base is an early enterprise in Yunnan Province that has passed the GMP certification of the State Food and Drug Administration. It has become a key support for the Yunnan Provincial Party Committee and Government to develop the "cloud medicine" industry. Pillar enterprise. The company's main product, "Detoxification and Beauty Capsules", has been on the market in 1995 and has continued to sell well for more than 20 years. It has maintained its forefront position in the detoxification drug market. In 1998, sales exceeded 1 billion mark. Based on technology and daring to be the first, the company has created a new pattern of China's Panax notoginseng industry, becoming a leading enterprise in Yunnan's unique resource-based Sanqi industry, and an enterprise exporting Sanqi products to the US market. According to the company's strategic development, we have used our many years of pharmaceutical advantage resources to enter the daily chemical field. By leveraging Yunnan's authentic resources such as Panax notoginseng, Dendrobium, Matsutake, Dragon Blood Tree, etc., we have successfully developed and operated "Siliwei" (skin care products) At the same time, it has laid out the field of food health, developed a series of natural, organic and healthy products such as expensive and fine medicinal materials and specialty foods, and fully enriched product cluster operation system, providing a successful example for the modernization and international development of traditional Chinese medicine enterprises. .
Yunnan Panlongyunhai Pharmaceutical Trading Co., Ltd.
Yunnan Panlong Yunhai Pharmaceutical Group Co., Ltd. (Yunnan Panlong Yunhai Pharmaceutical Management Co., Ltd. is an affiliated enterprise of Yunnan Panlong Yunhai Pharmaceutical Group Co., Ltd.) was founded in January 1994. It is a drug development, development and production. International pharmaceutical enterprise group integrating sales, the company actively innovates and explores management theories and development models suitable for the development and growth of Chinese private enterprises, and innovatively proposes traditional Chinese medicine health care that "detoxification and health care" and "internal adjustment and external care, healthy and beautiful" Theory has created a new era of detoxification and health preservation in China. The company's headquarters is located in Kunming High-tech Industrial Development Zone. Panlong Yunhai Production Base is an early enterprise in Yunnan Province that has passed the GMP certification of the State Food and Drug Administration. It has become a key support for the Yunnan Provincial Party Committee and Government to develop the "cloud medicine" industry. Pillar enterprise. The company's main product, "Detoxification and Beauty Capsules", has been on the market in 1995 and has continued to sell well for more than 20 years. It has maintained its forefront position in the detoxification drug market. In 1998, sales exceeded 1 billion mark. Based on technology and daring to be the first, the company has created a new pattern of China's Panax notoginseng industry, becoming a leading enterprise in Yunnan's unique resource-based Sanqi industry, and an enterprise exporting Sanqi products to the US market. According to the company's strategic development, we have used our many years of pharmaceutical advantage resources to enter the daily chemical field. By leveraging Yunnan's authentic resources such as Panax notoginseng, Dendrobium, Matsutake, Dragon Blood Tree, etc., we have successfully developed and operated "Siliwei" (skin care products) At the same time, it has laid out the field of food health, developed a series of natural, organic and healthy products such as expensive and fine medicinal materials and specialty foods, and fully enriched product cluster operation system, providing a successful example for the modernization and international development of traditional Chinese medicine enterprises. .
Tasly Biomedical Industry Group Co., Ltd.
Tianshili was founded in 1994. It is a high-tech enterprise group guided by internationalization, with the big health industry as the main line, the life medicine industry as the core, and the life health industry as the coordinated. The core enterprise, Tianshili Pharmaceutical Group Co., Ltd., was listed on the Shanghai Stock Exchange in 2002. Tianshili Pharmaceutical Group focuses on developing the life medicine industry in the big health industry system. Based on the technical positioning of large biomedicine, regenerative medicine and biomedical engineering, we adhere to the development of high-tech, high intelligence and high-end. Standardization and intelligence are achieved through a series of modern Chinese medicine internationalization guide industries represented by compound Danshen Drip Pills. The company has created a high-speed drop pill production line and a digital intelligent extraction production line of traditional Chinese medicine. On the basis of innovative modern Chinese medicine, it has linked international cutting-edge technologies through the "four-in-one" R&D model of independent research and development, cooperative research and development, product introduction, and investment market licensing priority. Do special and optimize the study of medicines, and make new and high-quality biological medicines. Positioning with optional urgent needs, fair self-payment, and technological upgrades, we will foresee the layout of new businesses such as cell therapy, Internet chronic diseases + digital therapy, and high-intensity focus ultrasound technology, and create integrated around the prevention, diagnosis, treatment and health of major chronic diseases. Solution, establish a health management function network. Tianshili Big Health Industry Investment Group focuses on developing the life and health industry in the big health industry system. Closely focusing on the core elements of healthy life and personalized users' needs, taking resource industries as a breakthrough, and taking Guotai Wine Industry Group as the leader, it will drive the development of Diboer tea treasure series and healthy functional foods and C-cell vibrant mineral water industry, through Technological innovation and product culture are demonstrated to enhance the consumption experience of healthy products. Tianshili adheres to industry-oriented, finance-oriented, and industrial-financial interaction. Establish an industrial capital platform - Tianshili Capital, positioned with "industry + capital", and focuses on "specialization, specialization and innovation" to strengthen, supplement and create chains, empower real industries to innovate and upgrade, and realize value creation and operation. Focusing on the fields of cardiovascular, tumors, digestive and metabolism, through investment linkage of 4D (Diagnosis diagnostic screening, Drug innovative drugs, Device medical devices and wearable devices, Digital digital therapy), we will build a great health value that is linked and empowered by each other. Ecology. Looking to the future, Tianshili will use modern science and technology and platforms such as artificial intelligence and big data to accelerate the "two transformations and one improvement" and transform into innovative and creative enterprises and smart service enterprises, from "product manufacturing as the core" to " With intelligent manufacturing with clustered products and systematic industrial chain as the core, we will upgrade, focus on building a "big health" ecosystem, we will be committed to innovating and developing, and contribute to the construction of a "healthy China".
Tasly Biomedical Industry Group Co., Ltd.
Tianshili was founded in 1994. It is a high-tech enterprise group guided by internationalization, with the big health industry as the main line, the life medicine industry as the core, and the life health industry as the coordinated. The core enterprise, Tianshili Pharmaceutical Group Co., Ltd., was listed on the Shanghai Stock Exchange in 2002. Tianshili Pharmaceutical Group focuses on developing the life medicine industry in the big health industry system. Based on the technical positioning of large biomedicine, regenerative medicine and biomedical engineering, we adhere to the development of high-tech, high intelligence and high-end. Standardization and intelligence are achieved through a series of modern Chinese medicine internationalization guide industries represented by compound Danshen Drip Pills. The company has created a high-speed drop pill production line and a digital intelligent extraction production line of traditional Chinese medicine. On the basis of innovative modern Chinese medicine, it has linked international cutting-edge technologies through the "four-in-one" R&D model of independent research and development, cooperative research and development, product introduction, and investment market licensing priority. Do special and optimize the study of medicines, and make new and high-quality biological medicines. Positioning with optional urgent needs, fair self-payment, and technological upgrades, we will foresee the layout of new businesses such as cell therapy, Internet chronic diseases + digital therapy, and high-intensity focus ultrasound technology, and create integrated around the prevention, diagnosis, treatment and health of major chronic diseases. Solution, establish a health management function network. Tianshili Big Health Industry Investment Group focuses on developing the life and health industry in the big health industry system. Closely focusing on the core elements of healthy life and personalized users' needs, taking resource industries as a breakthrough, and taking Guotai Wine Industry Group as the leader, it will drive the development of Diboer tea treasure series and healthy functional foods and C-cell vibrant mineral water industry, through Technological innovation and product culture are demonstrated to enhance the consumption experience of healthy products. Tianshili adheres to industry-oriented, finance-oriented, and industrial-financial interaction. Establish an industrial capital platform - Tianshili Capital, positioned with "industry + capital", and focuses on "specialization, specialization and innovation" to strengthen, supplement and create chains, empower real industries to innovate and upgrade, and realize value creation and operation. Focusing on the fields of cardiovascular, tumors, digestive and metabolism, through investment linkage of 4D (Diagnosis diagnostic screening, Drug innovative drugs, Device medical devices and wearable devices, Digital digital therapy), we will build a great health value that is linked and empowered by each other. Ecology. Looking to the future, Tianshili will use modern science and technology and platforms such as artificial intelligence and big data to accelerate the "two transformations and one improvement" and transform into innovative and creative enterprises and smart service enterprises, from "product manufacturing as the core" to " With intelligent manufacturing with clustered products and systematic industrial chain as the core, we will upgrade, focus on building a "big health" ecosystem, we will be committed to innovating and developing, and contribute to the construction of a "healthy China".
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
Zhangzhou Pianzihuang Pharmaceutical Co., Ltd. is a time-honored Chinese enterprise with its main business in pharmaceutical manufacturing. It was restructured and established in 1999 by Zhangzhou Pharmaceutical Factory, which was established in 1956, and was listed on the Shanghai Stock Exchange in 2003 with a current share capital of 603 million. The company is located in Zhangzhou High-tech Zone, covering an area of 114.88 mu. It now has 13 directly controlled subsidiaries and 9 shareholders, with about 2,700 employees. It has established production and medicinal materials bases in many provinces and municipalities across the country. It is a national high-tech enterprise, National technological innovation demonstration enterprise, national intellectual property demonstration enterprise, and national civilized unit. The company produces more than 20 Chinese patent medicines, including Pianzihuang, Angong Niuhuang Pills, Compound Pianzihuang Lozeng, Yindanpinggan Capsules, etc. The core product Pianzihuang is a national first-class traditional Chinese medicine protected variety. Its traditional production skills are included in the National Intangible Cultural Heritage List. It has been ranked among the forefront of China's single-species export of Chinese patent medicines for many years and is known as the "China symbol" on the "Maritime Silk Road".
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
Zhangzhou Pianzihuang Pharmaceutical Co., Ltd. is a time-honored Chinese enterprise with its main business in pharmaceutical manufacturing. It was restructured and established in 1999 by Zhangzhou Pharmaceutical Factory, which was established in 1956, and was listed on the Shanghai Stock Exchange in 2003 with a current share capital of 603 million. The company is located in Zhangzhou High-tech Zone, covering an area of 114.88 mu. It now has 13 directly controlled subsidiaries and 9 shareholders, with about 2,700 employees. It has established production and medicinal materials bases in many provinces and municipalities across the country. It is a national high-tech enterprise, National technological innovation demonstration enterprise, national intellectual property demonstration enterprise, and national civilized unit. The company produces more than 20 Chinese patent medicines, including Pianzihuang, Angong Niuhuang Pills, Compound Pianzihuang Lozeng, Yindanpinggan Capsules, etc. The core product Pianzihuang is a national first-class traditional Chinese medicine protected variety. Its traditional production skills are included in the National Intangible Cultural Heritage List. It has been ranked among the forefront of China's single-species export of Chinese patent medicines for many years and is known as the "China symbol" on the "Maritime Silk Road".
Guangxi Golden Throat Co., Ltd.
Guangxi Jinxun Group is an excellent technology-based enterprise in the pharmaceutical industry in the country. The group was originally Liuzhou Candy Factory No. 2 and was founded on March 6, 1956. In 1994, the company raised 7.8 million yuan to establish Guangxi Jinxu Pharmaceutical Factory. In 1998, it was restructured and established by Guangxi Jinxu Pharmaceutical Factory and Liuzhou Candy Factory No. 2. The company has an annual production capacity of 5 billion Jinxun throat tablets, with an annual output value of 1 billion. The company focuses on the pharmaceutical and food health industries. Its main products include more than 60 drugs such as Jinxun throat tablets, sugar-free Jinxun throat treasures, Jinxun health sugar, Jinxun Panax notoginseng capsules, Ginkgo leaves, Luohanguo Polygonatum granules, and Laotusiyuan More than ten traditional foods such as spring wine, peanut nougat, mooncakes, etc. Among them, the product Jinxun throat tablets has the effects of relieving wind and clearing heat, detoxifying and relieving throat, and aromatic foul-free. It is very popular among consumers. Its market share in similar products has been among the top for many years and has been exported to the United States, Canada, the European Union, and Russia. , Australia and Southeast Asia and more than 20 countries and regions. The company has passed GMP certification for drug production quality management specifications, HACCP certification for food safety management systems, ISO9001:2000 quality management system certification, ISO22000 food safety system certification, measurement management system certification, export food hygiene registration certification, US FDA certification, EU COM Certification, Australian health food certification, Malaysian Ministry of Health certification, Indonesian Ministry of Health registration certification. The benefits are in the present and the future. Looking forward to the future, Guangxi Jinxun Co., Ltd. will achieve more brilliant achievements to serve the motherland and the people.
Guangxi Golden Throat Co., Ltd.
Guangxi Jinxun Group is an excellent technology-based enterprise in the pharmaceutical industry in the country. The group was originally Liuzhou Candy Factory No. 2 and was founded on March 6, 1956. In 1994, the company raised 7.8 million yuan to establish Guangxi Jinxu Pharmaceutical Factory. In 1998, it was restructured and established by Guangxi Jinxu Pharmaceutical Factory and Liuzhou Candy Factory No. 2. The company has an annual production capacity of 5 billion Jinxun throat tablets, with an annual output value of 1 billion. The company focuses on the pharmaceutical and food health industries. Its main products include more than 60 drugs such as Jinxun throat tablets, sugar-free Jinxun throat treasures, Jinxun health sugar, Jinxun Panax notoginseng capsules, Ginkgo leaves, Luohanguo Polygonatum granules, and Laotusiyuan More than ten traditional foods such as spring wine, peanut nougat, mooncakes, etc. Among them, the product Jinxun throat tablets has the effects of relieving wind and clearing heat, detoxifying and relieving throat, and aromatic foul-free. It is very popular among consumers. Its market share in similar products has been among the top for many years and has been exported to the United States, Canada, the European Union, and Russia. , Australia and Southeast Asia and more than 20 countries and regions. The company has passed GMP certification for drug production quality management specifications, HACCP certification for food safety management systems, ISO9001:2000 quality management system certification, ISO22000 food safety system certification, measurement management system certification, export food hygiene registration certification, US FDA certification, EU COM Certification, Australian health food certification, Malaysian Ministry of Health certification, Indonesian Ministry of Health registration certification. The benefits are in the present and the future. Looking forward to the future, Guangxi Jinxun Co., Ltd. will achieve more brilliant achievements to serve the motherland and the people.
Jiangxi Jinshuibao Pharmaceutical Co., Ltd.
Jinshuibao Pharmaceutical was established in 1992. It is an intensive high-tech pharmaceutical production enterprise integrating scientific research, production and sales. It is a wholly-owned subsidiary of Jiangxi Jimin Trust Holding Group and a strategic brand in the field of big health. Currently, Jinshuibao Pharmaceutical has multiple products such as medicines, health products, and health foods. It has many sub-brands such as Jinshuibao, Huangshi, Jiuhua, Kutong, Yanbaotang, etc., Jinshuibao Capsules, Huangshi Xiangsheng Pills, and Jinshuibao Gold capsules, Shuangyi capsules, Jiuhua hemorrhoid suppositories, Liuwei Dihuang Drip Pills and other gold products. Jinshuibao Pharmaceutical takes "innovation" and "inheritance" as the core concept of the enterprise, takes careful development as the specific method, and takes better efficacy as the ultimate goal to create more outstanding products. In the future, Jinshuibao Pharmaceutical will innovate in the field of big health, and is committed to the mission of "research on good medicines to benefit the people" and strive for eternal human health.
Jiangxi Jinshuibao Pharmaceutical Co., Ltd.
Jinshuibao Pharmaceutical was established in 1992. It is an intensive high-tech pharmaceutical production enterprise integrating scientific research, production and sales. It is a wholly-owned subsidiary of Jiangxi Jimin Trust Holding Group and a strategic brand in the field of big health. Currently, Jinshuibao Pharmaceutical has multiple products such as medicines, health products, and health foods. It has many sub-brands such as Jinshuibao, Huangshi, Jiuhua, Kutong, Yanbaotang, etc., Jinshuibao Capsules, Huangshi Xiangsheng Pills, and Jinshuibao Gold capsules, Shuangyi capsules, Jiuhua hemorrhoid suppositories, Liuwei Dihuang Drip Pills and other gold products. Jinshuibao Pharmaceutical takes "innovation" and "inheritance" as the core concept of the enterprise, takes careful development as the specific method, and takes better efficacy as the ultimate goal to create more outstanding products. In the future, Jinshuibao Pharmaceutical will innovate in the field of big health, and is committed to the mission of "research on good medicines to benefit the people" and strive for eternal human health.
Yangtze River Pharmaceutical Group Co., Ltd.
Founded in 1971, Yangtze River Pharmaceutical Group is a large national pharmaceutical enterprise group and an early innovative enterprise named by the Ministry of Science and Technology. The group is headquartered in Taizhou City, Jiangsu Province, with more than 16,000 employees. More than 20 member companies are located in Taizhou, Beijing, Shanghai, Nanjing, Guangzhou, Chengdu, Suzhou, Changzhou and other places; the marketing network covers all provinces and cities across the country except Taiwan. ,autonomous region. The group practices the core values of "high-quality benefiting the people and innovation and goodness" and focuses on providing high-quality medicines and health services to the society. The Group implements the development policy of "quality first and efficiency first" and has multiple innovative R&D platforms. The Yangtze River water nurtures China, and the Yangtze River medicine benefits China. Under the guidance of the spirit of the 19th National Congress of the Communist Party of China, Yangtze River Pharmaceutical has continued to deepen supply-side structural reform, implemented the big health industry strategy, kept its original aspiration in mind, kept its mission in mind, forged ahead, and strived to achieve the 13th Five-Year Plan sales target of 100 billion yuan. Aspire to become a world-renowned pharmaceutical company in the field of health.
Yangtze River Pharmaceutical Group Co., Ltd.
Founded in 1971, Yangtze River Pharmaceutical Group is a large national pharmaceutical enterprise group and an early innovative enterprise named by the Ministry of Science and Technology. The group is headquartered in Taizhou City, Jiangsu Province, with more than 16,000 employees. More than 20 member companies are located in Taizhou, Beijing, Shanghai, Nanjing, Guangzhou, Chengdu, Suzhou, Changzhou and other places; the marketing network covers all provinces and cities across the country except Taiwan. ,autonomous region. The group practices the core values of "high-quality benefiting the people and innovation and goodness" and focuses on providing high-quality medicines and health services to the society. The Group implements the development policy of "quality first and efficiency first" and has multiple innovative R&D platforms. The Yangtze River water nurtures China, and the Yangtze River medicine benefits China. Under the guidance of the spirit of the 19th National Congress of the Communist Party of China, Yangtze River Pharmaceutical has continued to deepen supply-side structural reform, implemented the big health industry strategy, kept its original aspiration in mind, kept its mission in mind, forged ahead, and strived to achieve the 13th Five-Year Plan sales target of 100 billion yuan. Aspire to become a world-renowned pharmaceutical company in the field of health.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Company" and "Zhongsheng Pharmaceutical") was founded in 1979. It is an A-share listed company integrating drug research and development, production and sales. The company implements the value of "patient interests first", adheres to the corporate purpose of "caring for life with high-quality products and serving healthy people with high-quality", and is based on the treatment fields of ophthalmology, cardiovascular, respiratory, digestive and other treatments, with pharmaceutical manufacturing as its core business. , adhere to the development path of dual-wheel drive of R&D innovation and marketing innovation, gradually form a sustainable development business system with innovative drugs as the leader in development, traditional Chinese patent medicine as the cornerstone of business, and chemical generic drugs as the beneficial support, and be determined to become China's advanced pharmaceutical and health industry group. The company's main business covers the research and development, production and sales of traditional Chinese medicines, chemical medicines, Chinese medicinal materials, Chinese herbal medicines, chemical raw materials, and investment in ophthalmology related industries. It has ten subsidiaries covering pharmaceutical, pharmaceutical, trade, innovative R&D and ophthalmology investment. There are four major production bases in Dongguan, Guangzhou, Zhaoqing and Qujing. The company adheres to the development concept of "R&D and innovation are the primary productive forces", aims to "meet unmet clinical needs" and "research and development varieties with unique clinical value". By establishing a multi-modal virtuous cycle R&D ecosystem, we are committed to Research and development of innovative drugs for public health and safety, major chronic diseases. Through its stake in the South China New Drug Creation Center, the company introduced the Guangdong Provincial Innovation Team, and strategic cooperation with WuXi AppTec and the National Clinical Medical Research Center for Respiratory Diseases (Academician Zhong Nanshan’s team), focusing on influenza and non-alcoholic steatohepatitis ( NASH), ophthalmology, tumors and metabolic diseases and other special areas have been carried out to develop innovative drugs. At the same time, the company seized the historic opportunities of generic drug consistency evaluation and national centralized procurement, and steadily promoted the consistency evaluation of generic drug. The company continues to implement the business strategy of "full products, all terminals, and all channels", builds a chronic disease product line around core products, deepens the grassroots pharmaceutical market in small and medium-sized cities, increases county-level terminal coverage, innovates professional academic promotion system, and through digitalization Technology empowers marketing and explores new business models.
Pharmaceutical Co., Ltd.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Company" and "Zhongsheng Pharmaceutical") was founded in 1979. It is an A-share listed company integrating drug research and development, production and sales. The company implements the value of "patient interests first", adheres to the corporate purpose of "caring for life with high-quality products and serving healthy people with high-quality", and is based on the treatment fields of ophthalmology, cardiovascular, respiratory, digestive and other treatments, with pharmaceutical manufacturing as its core business. , adhere to the development path of dual-wheel drive of R&D innovation and marketing innovation, gradually form a sustainable development business system with innovative drugs as the leader in development, traditional Chinese patent medicine as the cornerstone of business, and chemical generic drugs as the beneficial support, and be determined to become China's advanced pharmaceutical and health industry group. The company's main business covers the research and development, production and sales of traditional Chinese medicines, chemical medicines, Chinese medicinal materials, Chinese herbal medicines, chemical raw materials, and investment in ophthalmology related industries. It has ten subsidiaries covering pharmaceutical, pharmaceutical, trade, innovative R&D and ophthalmology investment. There are four major production bases in Dongguan, Guangzhou, Zhaoqing and Qujing. The company adheres to the development concept of "R&D and innovation are the primary productive forces", aims to "meet unmet clinical needs" and "research and development varieties with unique clinical value". By establishing a multi-modal virtuous cycle R&D ecosystem, we are committed to Research and development of innovative drugs for public health and safety, major chronic diseases. Through its stake in the South China New Drug Creation Center, the company introduced the Guangdong Provincial Innovation Team, and strategic cooperation with WuXi AppTec and the National Clinical Medical Research Center for Respiratory Diseases (Academician Zhong Nanshan’s team), focusing on influenza and non-alcoholic steatohepatitis ( NASH), ophthalmology, tumors and metabolic diseases and other special areas have been carried out to develop innovative drugs. At the same time, the company seized the historic opportunities of generic drug consistency evaluation and national centralized procurement, and steadily promoted the consistency evaluation of generic drug. The company continues to implement the business strategy of "full products, all terminals, and all channels", builds a chronic disease product line around core products, deepens the grassroots pharmaceutical market in small and medium-sized cities, increases county-level terminal coverage, innovates professional academic promotion system, and through digitalization Technology empowers marketing and explores new business models.
Chongqing Watson Pharmaceutical Co., Ltd.
Huasen Pharmaceutical (stock code: 002907) is a national key high-tech enterprise integrating scientific research, production and sales, and a large comprehensive modern pharmaceutical enterprise in China. It has established a post-Bo Scientific Research Workstation and Chongqing City Haizhi workstation. Huasen Pharmaceuticals is owned by Beijing Huasen Inno Biotechnology Co., Ltd., Beijing Bosen Biotechnology Co., Ltd., Pharscin US Inc. (Huasen Pharmaceutical (US) Co., Ltd.), Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., Chongqing Huasen Pharmacy Retail Chain Co., Ltd. Huasen Pharmaceuticals is based on the concept of "technology-led, innovation-driven, inheriting the essence, adhering to the truth and innovation", and creating high-quality products that are "specialized, refined, special and new". Currently, the company has 77 drug approval documents, including Chinese patent medicines, chemical raw materials and preparations, and has 1 US ANDA equity product, including 56 drugs in the national "medical insurance" catalog, 49 national drug standards, and 72 patents. It undertakes 120 scientific and technological research and development projects in various national, provincial and municipal ministries and commissions. In terms of innovative drug research and development, Watson Pharmaceuticals (Wassen Inno) has promoted a differentiated R&D pipeline and is committed to building an innovative drug research and development team with an international perspective, focusing on small-molecular drugs in the fields of tumors, tumor immunity and self-invigorating diseases. Development has already had 4 independently developed innovative drugs in tumor category 1.1, and its potential indications cover tumor immunity and lung cancer, breast cancer, colorectal cancer, pancreatic cancer and other solid tumors; it has been built to develop multiple innovative drugs. platform. In terms of external cooperation in innovative drugs, we cooperated with the scientific research achievement conversion platform of the scientist team of the National Key Laboratory of Biotherapy of Sichuan University to invest in the establishment of Chengdu Aoru Pharmaceutical Co., Ltd., a technology platform based on artificial intelligence drug discovery dedicated to small molecule targeting New drug research and development company for innovative drugs; cooperate with Zhongke Computing Technology Western Research Institute and Beijing Zheyuan Technology Co., Ltd. to screen new tumor drug targets, drug candidate development, translational medicine research, preclinical and clinical development, registration and application, market approval and other work to create a new height for biomedical innovation. In terms of generic drugs, Chinese patent medicines and special medical food research and development, the company has implemented the R&D strategy of "excellent production costs, fast R&D speed, and high technical barriers", and has laid out the digestive system, mental nervous system, respiratory system, tumor, and postoperative reduction. In the fields of heavy and heavy industry, through the continuous accumulation of project experience, eight national R&D technologies have been established, including “Raw Materials Engineering Transformation Research Platform, Industrial Pharmaceutical Prescription Design and Process Amplification Research Platform, CMC (Chemical and Quality Control) and Impurity Quantitative Analysis Research Platform”. The company has established a testing center in the construction of common R&D platforms, which has passed the CNAS certification. Huasen Pharmaceutical takes "developing good medicines, healthy human beings, and achieving employees" as its corporate mission, upholds the values of "integrity, diligence, gratitude, learning, teamwork, innovation", and uses solid steps to "make good Chinese medicine and go to the world" The Huasen Dream has been striving forever, contributing to the construction of the Chengdu-Chongqing Twin Cities Economic Circle and contributing to the realization of the Chinese dream of the great rejuvenation of the Chinese nation.
Chongqing Watson Pharmaceutical Co., Ltd.
Huasen Pharmaceutical (stock code: 002907) is a national key high-tech enterprise integrating scientific research, production and sales, and a large comprehensive modern pharmaceutical enterprise in China. It has established a post-Bo Scientific Research Workstation and Chongqing City Haizhi workstation. Huasen Pharmaceuticals is owned by Beijing Huasen Inno Biotechnology Co., Ltd., Beijing Bosen Biotechnology Co., Ltd., Pharscin US Inc. (Huasen Pharmaceutical (US) Co., Ltd.), Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., Chongqing Huasen Pharmacy Retail Chain Co., Ltd. Huasen Pharmaceuticals is based on the concept of "technology-led, innovation-driven, inheriting the essence, adhering to the truth and innovation", and creating high-quality products that are "specialized, refined, special and new". Currently, the company has 77 drug approval documents, including Chinese patent medicines, chemical raw materials and preparations, and has 1 US ANDA equity product, including 56 drugs in the national "medical insurance" catalog, 49 national drug standards, and 72 patents. It undertakes 120 scientific and technological research and development projects in various national, provincial and municipal ministries and commissions. In terms of innovative drug research and development, Watson Pharmaceuticals (Wassen Inno) has promoted a differentiated R&D pipeline and is committed to building an innovative drug research and development team with an international perspective, focusing on small-molecular drugs in the fields of tumors, tumor immunity and self-invigorating diseases. Development has already had 4 independently developed innovative drugs in tumor category 1.1, and its potential indications cover tumor immunity and lung cancer, breast cancer, colorectal cancer, pancreatic cancer and other solid tumors; it has been built to develop multiple innovative drugs. platform. In terms of external cooperation in innovative drugs, we cooperated with the scientific research achievement conversion platform of the scientist team of the National Key Laboratory of Biotherapy of Sichuan University to invest in the establishment of Chengdu Aoru Pharmaceutical Co., Ltd., a technology platform based on artificial intelligence drug discovery dedicated to small molecule targeting New drug research and development company for innovative drugs; cooperate with Zhongke Computing Technology Western Research Institute and Beijing Zheyuan Technology Co., Ltd. to screen new tumor drug targets, drug candidate development, translational medicine research, preclinical and clinical development, registration and application, market approval and other work to create a new height for biomedical innovation. In terms of generic drugs, Chinese patent medicines and special medical food research and development, the company has implemented the R&D strategy of "excellent production costs, fast R&D speed, and high technical barriers", and has laid out the digestive system, mental nervous system, respiratory system, tumor, and postoperative reduction. In the fields of heavy and heavy industry, through the continuous accumulation of project experience, eight national R&D technologies have been established, including “Raw Materials Engineering Transformation Research Platform, Industrial Pharmaceutical Prescription Design and Process Amplification Research Platform, CMC (Chemical and Quality Control) and Impurity Quantitative Analysis Research Platform”. The company has established a testing center in the construction of common R&D platforms, which has passed the CNAS certification. Huasen Pharmaceutical takes "developing good medicines, healthy human beings, and achieving employees" as its corporate mission, upholds the values of "integrity, diligence, gratitude, learning, teamwork, innovation", and uses solid steps to "make good Chinese medicine and go to the world" The Huasen Dream has been striving forever, contributing to the construction of the Chengdu-Chongqing Twin Cities Economic Circle and contributing to the realization of the Chinese dream of the great rejuvenation of the Chinese nation.
Longjiao San is a pharmaceutical company focusing on throats and is also a well-known family medicine brand in Japan. It has a history of more than 200 years. Its main products include throat medicine, throat lozenges, and medication-assisted jelly. "Dragon Kaeda" was a royal medicine passed down by Satakehou, the king of Akita in the Edo period, and was invented by the royal doctor of the vassal king and Genzo Fujii. The prescription at that time contained keel bone, dragon head and deer antler cream and was a powder, so it was named. The Fujii family has been imperial physicians of the vassal kings for generations. After learning Orchid (Western Science and Technology), the second-generation descendant, Gennobu Fujii, added Western herbs to the prescription. In the early Meiji period, in order to treat the asthma of the vassal kings, the third-generation famous doctor, Masatoji Fujii, improved Longjiao San into a prescription for treating asthma, laying the foundation for the current Longjiao San prescription. After the Meiji Restoration, due to the political reform of abolishing the vassal state, the vassal kingdom disappeared. Fujii Masatoi, who moved to Edo (now Tokyo), was granted "Ryukaku San" by the vassal king. In 1871, he was awarded "Ryukaku San" in Kanda, Tokyo. Pharmacies are opened in the area. The "secret medicine" exclusive to the vassal kings has also been transformed into a product sold to the general public. In 1893, the fourth generation of Fujii Tosaburo further improved the "Rongjiao San" and ground several herbs into 10-20μm micro powder and mixed and processed, achieving the current "Rongjiao San".
Ryukakusan Co., Ltd.
Longjiao San is a pharmaceutical company focusing on throats and is also a well-known family medicine brand in Japan. It has a history of more than 200 years. Its main products include throat medicine, throat lozenges, and medication-assisted jelly. "Dragon Kaeda" was a royal medicine passed down by Satakehou, the king of Akita in the Edo period, and was invented by the royal doctor of the vassal king and Genzo Fujii. The prescription at that time contained keel bone, dragon head and deer antler cream and was a powder, so it was named. The Fujii family has been imperial physicians of the vassal kings for generations. After learning Orchid (Western Science and Technology), the second-generation descendant, Gennobu Fujii, added Western herbs to the prescription. In the early Meiji period, in order to treat the asthma of the vassal kings, the third-generation famous doctor, Masatoji Fujii, improved Longjiao San into a prescription for treating asthma, laying the foundation for the current Longjiao San prescription. After the Meiji Restoration, due to the political reform of abolishing the vassal state, the vassal kingdom disappeared. Fujii Masatoi, who moved to Edo (now Tokyo), was granted "Ryukaku San" by the vassal king. In 1871, he was awarded "Ryukaku San" in Kanda, Tokyo. Pharmacies are opened in the area. The "secret medicine" exclusive to the vassal kings has also been transformed into a product sold to the general public. In 1893, the fourth generation of Fujii Tosaburo further improved the "Rongjiao San" and ground several herbs into 10-20μm micro powder and mixed and processed, achieving the current "Rongjiao San".
Fleetwood Loft House Limited (UK)
Fisherman's Friend is a powerful mint-throated candy developed by a pharmacist named James Lofthouse in 1865 to alleviate various breathing problems caused by fishermen's harsh environments in Iceland's fishing sites. Originally a potion containing mint and eucalyptus oil, Lofthouse made this liquid into throat candy to make it easier to transport and manage. Soon the fishermen began to liken this throat candy to their "friends", which is also the origin of its name. This throat lozenges can effectively relieve cough symptoms caused by colds. Today, the "Fisherman's Treasure" markets many countries around the world. The way of success lies in maintaining consistent good product quality, which makes people feel unspeakable and refreshing. It has been carried out in an attempt to make it in the international market. High status. Fisherman's Treasure Original Throat Lotion dates back to 1865. Fisherman's Treasure's Special Mint-flavored throat candy appeared in the early 1980s. As demand for sugar-free products continued to increase, the company launched sugar-free mint-flavored throat candy in 1991. 1997 was an important year because the company launched the fruit-flavored throat lozenges, Fisherman's Bonuses Specialty Throat Lozenges (lemon flavor - sugar-free). Since its launch in the Asian market, citrus grapefruit-flavored throat candy has become one of the popular flavors. Fisherman's Treasure is now available in a variety of flavors, some of which are only available in specific areas. The striped ones on the packaging are sugar-free.
Fleetwood Loft House Limited (UK)
Fisherman's Friend is a powerful mint-throated candy developed by a pharmacist named James Lofthouse in 1865 to alleviate various breathing problems caused by fishermen's harsh environments in Iceland's fishing sites. Originally a potion containing mint and eucalyptus oil, Lofthouse made this liquid into throat candy to make it easier to transport and manage. Soon the fishermen began to liken this throat candy to their "friends", which is also the origin of its name. This throat lozenges can effectively relieve cough symptoms caused by colds. Today, the "Fisherman's Treasure" markets many countries around the world. The way of success lies in maintaining consistent good product quality, which makes people feel unspeakable and refreshing. It has been carried out in an attempt to make it in the international market. High status. Fisherman's Treasure Original Throat Lotion dates back to 1865. Fisherman's Treasure's Special Mint-flavored throat candy appeared in the early 1980s. As demand for sugar-free products continued to increase, the company launched sugar-free mint-flavored throat candy in 1991. 1997 was an important year because the company launched the fruit-flavored throat lozenges, Fisherman's Bonuses Specialty Throat Lozenges (lemon flavor - sugar-free). Since its launch in the Asian market, citrus grapefruit-flavored throat candy has become one of the popular flavors. Fisherman's Treasure is now available in a variety of flavors, some of which are only available in specific areas. The striped ones on the packaging are sugar-free.
Siping Vickers Heat Exchange Equipment Co., Ltd.
China Siping Vickers Heat Exchange Equipment Co., Ltd. is a core member unit of Vickers International Group. It is currently one of the largest and most comprehensive professional manufacturing companies for heat exchange equipment in Asia. The design, manufacturing and R&D base of Vickers International Group is composed of branches with regional centers such as France, the United States, and Singapore, and its sales service network is spread all over the world. Integrating international advanced technology, Viex Group continues to innovate, and now ViEX has become a world-renowned manufacturer of heat exchange equipment. Over the past few decades, from Siping Heat Exchanger Factory to Siping Vickers Company, it has developed leap forward and bigger and stronger. The current garden-style factory covers an area of 60,000 square meters and has a construction area of 26,000 square meters. In 2004, after introducing the complete set of French fine molds and production processes, it has been continuously improved and optimized. Now we have 310 sets of various production, processing and inspection equipment. There are 460 fixed employees in the enterprise. Among them, scientific and technological personnel account for about 50% of the total number of employees. With the completion of the renovation of the old industrial base project in Northeast China, the company has expanded its production scale and capacity. Business scope Heat exchange equipment, environmental protection equipment and their edge products design, manufacturing, and sales; import and export of goods; import and export of technology and their agents. Corporate capabilities It produces 200,000 square meters and 4,000 sets (sets) of various heat exchange equipment annually. Annual sales of RMB 300 million, of which exports earn US$10 million.
Siping Vickers Heat Exchange Equipment Co., Ltd.
China Siping Vickers Heat Exchange Equipment Co., Ltd. is a core member unit of Vickers International Group. It is currently one of the largest and most comprehensive professional manufacturing companies for heat exchange equipment in Asia. The design, manufacturing and R&D base of Vickers International Group is composed of branches with regional centers such as France, the United States, and Singapore, and its sales service network is spread all over the world. Integrating international advanced technology, Viex Group continues to innovate, and now ViEX has become a world-renowned manufacturer of heat exchange equipment. Over the past few decades, from Siping Heat Exchanger Factory to Siping Vickers Company, it has developed leap forward and bigger and stronger. The current garden-style factory covers an area of 60,000 square meters and has a construction area of 26,000 square meters. In 2004, after introducing the complete set of French fine molds and production processes, it has been continuously improved and optimized. Now we have 310 sets of various production, processing and inspection equipment. There are 460 fixed employees in the enterprise. Among them, scientific and technological personnel account for about 50% of the total number of employees. With the completion of the renovation of the old industrial base project in Northeast China, the company has expanded its production scale and capacity. Business scope Heat exchange equipment, environmental protection equipment and their edge products design, manufacturing, and sales; import and export of goods; import and export of technology and their agents. Corporate capabilities It produces 200,000 square meters and 4,000 sets (sets) of various heat exchange equipment annually. Annual sales of RMB 300 million, of which exports earn US$10 million.
